BioCardia's Helix Catheter Gains FDA Approval for Marketing Clearance; Stock Rises

BioCardia's Helix Catheter has gained FDA review and is scheduled for a substantive review and meeting in Q2. The catheter is designed to deliver therapeutic agents directly into the heart muscle with greater precision and retention. FDA clearance would be a significant milestone for BioCardia and the broader cardiac therapeutics field. Upcoming catalysts include a pivotal Phase 3 program for CardiAMP cell therapy in patients with ischemic heart failure and a Phase 2 study exploring CardiAMP in patients with chest pain due to reduced blood flow. The stock price has risen 8.66% in pre-market trading.